ProKidney focuses on cell therapy for chronic kidney diseases, with REACT in Phase 3 trials and FDA's RMAT designation. Financially stable, with $446M in liquid assets and a 37-month cash runway, but ...
WINSTON-SALEM, N.C., Jan. 10, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback